Related Experiment Video

Updated: May 31, 2025

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

492

JAK inhibitors: a new choice for diabetes mellitus?

Mengjun Zhou1, Qi Shen2, Bo Li3

  • 1Department of Cardiology, Zibo Central Hospital, Binzhou Medical University, No. 10, South Shanghai Road, Zibo, People's Republic of China.

Diabetology & Metabolic Syndrome
|January 24, 2025
PubMed

Insights

Janus kinase (JAK) inhibitors show promise in treating diabetes mellitus by reducing beta-cell damage and improving insulin resistance. These nonreceptor-type tyrosine kinase inhibitors offer a new therapeutic avenue for managing diabetes.

Area of Science:

  • Biochemistry
  • Endocrinology
  • Pharmacology

Background:

  • Altered tyrosine kinase signaling is implicated in various diseases.
  • Tyrosine kinases are classified into receptor and nonreceptor types, with Janus kinases (JAKs) being a key nonreceptor subgroup.
  • Previous research highlighted the benefits of receptor-type tyrosine kinase inhibitors (TKIs) for diabetes mellitus (DM).

Purpose of the Study:

  • To review the beneficial effects of JAK inhibitors in treating diabetes mellitus (DM).
  • To analyze the underlying mechanisms of JAK inhibitors in DM treatment.
  • To explore JAK inhibitors as a therapeutic option within nonreceptor-type tyrosine kinase inhibitors.

Main Methods:

  • Literature review of clinical cases and studies on JAK inhibitors for diabetes.
  • Analysis of in vivo and in vitro experimental data.
  • Examination of mechanisms related to beta-cell preservation and insulin resistance.

Main Results:

  • Clinical reports indicate reversal of type 1 diabetes mellitus (T1DM) with JAK inhibitors.
  • Studies show improvement in type 2 diabetes mellitus (T2DM) during JAK inhibitor treatment.
  • Experimental evidence suggests reduced beta-cell disruption and enhanced insulin sensitivity.

Conclusions:

  • JAK inhibitors demonstrate therapeutic potential for diabetes mellitus.
  • Mechanisms involve protecting pancreatic beta cells and improving insulin resistance.
  • Further investigation into JAK inhibitors for DM management is warranted.
Keywords:
BaricitinibDiabetes mellitusJAK inhibitorsJAK-STATReviewTofacitinib

More Related Videos

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature10:07

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature

Published on: December 26, 2017

13.1K
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

193

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
165
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
165
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
148
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
294
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136